Cargando…

A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients

BACKGROUND AND OBJECTIVE: The tacrolimus concentration within peripheral blood mononuclear cells may correlate better with clinical outcomes after transplantation compared to concentrations measured in whole blood. However, intracellular tacrolimus measurements are not easily implemented in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franken, Linda G., Francke, Marith I., Andrews, Louise M., van Schaik, Ron H. N., Li, Yi, de Wit, Lucia E. A., Baan, Carla C., Hesselink, Dennis A., de Winter, Brenda C. M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232416/ https://www.ncbi.nlm.nih.gov/pubmed/35442010 http://dx.doi.org/10.1007/s13318-022-00767-8

Ejemplares similares

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
por: Francke, Marith I., et al.
Publicado: (2020)

Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
por: Francke, Marith I., et al.
Publicado: (2021)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose
por: Andrews, Louise M., et al.
Publicado: (2017)

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
por: Andrews, L. M., et al.
Publicado: (2019)

Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients
por: Kannegieter, Nynke M., et al.
Publicado: (2018)

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation
por: Andrews, Louise M., et al.
Publicado: (2017)

A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement
por: Andrews, Louise M., et al.
Publicado: (2019)

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients
por: Bunthof, Kim L. W., et al.
Publicado: (2021)

Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography–tandem mass spectrometry
por: Bahmany, Soma, et al.
Publicado: (2018)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)

Best Practices to Implement Dried Blood Spot Sampling for Therapeutic Drug Monitoring in Clinical Practice
por: Francke, Marith I., et al.
Publicado: (2022)

The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function
por: Kannegieter, Nynke M., et al.
Publicado: (2017)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2022)

Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial
por: Kannegieter, Nynke M., et al.
Publicado: (2017)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Immune Subsets From Ficoll Density Gradient Separation in Kidney Transplant Recipients
por: Udomkarnjananun, Suwasin, et al.
Publicado: (2022)

Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants
por: Han, Seung Seok, et al.
Publicado: (2012)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
por: Mansell, Holly, et al.
Publicado: (2022)

Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients
por: Martial, Lisa C., et al.
Publicado: (2021)

Costimulation Blockade in Kidney Transplant Recipients
por: van der Zwan, Marieke, et al.
Publicado: (2019)

Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients
por: Tornatore, Kathleen M., et al.
Publicado: (2022)

A Joint Pharmacokinetic Model for the Simultaneous Description of Plasma and Whole Blood Tacrolimus Concentrations in Kidney and Lung Transplant Recipients
por: Koomen, Jeroen V., et al.
Publicado: (2023)

Iron deficiency after kidney transplantation
por: Vinke, Joanna Sophia J, et al.
Publicado: (2020)

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
por: van der Zwan, Marieke, et al.
Publicado: (2017)

Direct detection of circulating donor-derived extracellular vesicles in kidney transplant recipients
por: Woud, Wouter W., et al.
Publicado: (2022)

Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function
por: Han, Seung Seok, et al.
Publicado: (2016)

High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation
por: Sikma, Maaike A., et al.
Publicado: (2019)

Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients
por: Thongprayoon, Charat, et al.
Publicado: (2020)

Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
por: Francke, Marith I., et al.
Publicado: (2021)

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients
por: Marfo, Kwaku, et al.
Publicado: (2010)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation
por: Sikma, Maaike A., et al.
Publicado: (2019)

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients
por: de Winter, Brenda C. M., et al.
Publicado: (2009)

Population pharmacokinetics of immediate‐ and prolonged‐release tacrolimus formulations in liver, kidney and heart transplant recipients
por: Lu, Zheng, et al.
Publicado: (2019)

The Impact of Single Nucleotide Polymorphisms on the Pharmacokinetics of Tacrolimus in Kidney Allograft Recipients of Northern-West, Iran
por: Jabbari Hagh, Elaheh, et al.
Publicado: (2023)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hhk52iotpf59rp2o60r5iuvlg9